Blueprint Medicines (BPMC) Q2 2024 earnings summary

Executive summary

• AYVAKIT net product revenues reached $114.1 million in Q2 2024, up over 185% year-over-year, with strong U.S. and international performance and label expansion for indolent SM.

• Full-year 2024 AYVAKIT revenue guidance was raised to $435–$450 million, reflecting confidence in continued commercial execution and market expansion.

• Net loss narrowed to $50.0 million in Q2 2024 from $132.8 million in Q2 2023, and six-month net income reached $39.1 million, primarily due to a $173.7 million debt extinguishment gain.

• Cash, cash equivalents, and investments totaled $868.5 million as of June 30, 2024, supporting ongoing R&D and commercial investments.

• Advanced pipeline with initiation of BLU-808 Phase 1 trial and progress on elenestinib and BLU-222 programs.

Financial highlights

• Q2 2024 total revenues were $138.2 million, up from $57.6 million in Q2 2023; six-month revenues were $234.3 million.

• AYVAKIT/AYVAKYT net product revenues were $114.1 million in Q2 2024 versus $39.9 million in Q2 2023.

• Net loss improved to $50.0 million in Q2 2024 from $132.8 million in Q2 2023; six-month net income was $39.1 million.

• R&D expenses decreased to $84.3 million in Q2 2024 from $110.1 million in Q2 2023; SG&A expenses rose to $89.3 million from $71.9 million.

• Cash, cash equivalents, and investments increased to $868.5 million as of June 30, 2024, from $767.2 million at year-end 2023.

Outlook and guidance

• AYVAKIT 2024 net product revenue guidance was raised to $435–$450 million, reflecting strong first-half performance and improved visibility into key business drivers.

• Guidance incorporates expectations for seasonality, stabilized free goods share, and the impact of German pricing negotiations.

• Anticipates maintaining a durable capital position and achieving a self-sustainable financial profile.

• R&D expenses are expected to decline in 2024 due to portfolio optimization, while SG&A expenses are expected to increase modestly.

• International launches, especially in Europe, are expected to contribute more significantly to growth in 2025 and beyond.